Circio Holding ASA — Targovax — Q4 2020 Earnings Presentation

5 slides from Circio Holding ASA's earnings presentation, February 2021

Slide 1: 4Q update
4Q update 7. Closing remarks ° targovax °
Slide 2: 4Q Highlights and Subsequent Events
4Q HIGHLIGHTS AND SUBSEQUENT EVENTS Announced 35% response rate in ONCOS-102 trial in anti-PD1 refractory melanoma patients and regression on non-injected lesions Completed Part 1 in the colorectal cancer trial, combining ONCOS-102 with ONCOS-102 Imfinzi (duravalumab), recruitment in Part 2 opened A
Slide 3: Update on IOVaxis License
UPDATE ON IOVAXIS LICENSE CEO: John Wang HQ: Nantong, China Founded: 2018 R&D focus: Shared and personalized cancer vaccines Description Update o Exclusive option to license TG01/02 o IOVaxis is still in IND application vaccines for Greater China and process with NMPA (Chinese FDA) Singapore o NMPA
Slide 4: Continued Cost Control in 4Q20
CONTINUED COST CONTROL IN 4Q20 NOK m 4Q19 1Q20 2Q20 3Q20 4Q20 Total revenue 2 0 0 0 -0 External R&D expenses -25 -13 -14 -9 -8 Payroll and related expenses -11 -11 -11 -9 -12 Other operating expenses -5 -5 -5 -4 -3 Total operating expenses -42 -30 -30 -22 -23 76
Slide 5: Currently Funded into 2022
CURRENTLY FUNDED INTO 2022 The company Share liquidity Cash at end of 4Q ~170% of shares traded last 12 months 122 14 Share turnover per month1 NOK million USD million Million shares Net cash flow - total 4Q 45 5.3 Capital raise in Oct 2020 NOK million USD million Market cap 850 100 NOK million USD